Report of Foreign Issuer (6-k)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2017

Commission File Number: 001-34541

CHINA CORD BLOOD CORPORATION

(Translation of registrant’s name into English)

48 th Floor, Bank of China Tower
1 Garden Road
Central
Hong Kong S.A.R.
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .

EXPLANATORY NOTE

This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or China Cord Blood Corporation’s (the “Company”) future financial performance. The Company has attempted to identify forward-looking statements by terminology including “anticipates”, “believes”, “expects”, “can”, “continue”, “could”, “estimates”, “intends”, “may”, “plans”, “potential”, “predict”, “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this Report on Form 6-K is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company’s expectations are as of the date of this Report on Form 6-K, and the Company does not intend to update any of the forward-looking statements after the date of this Report on Form 6-K to conform these statements to actual results, unless required by law.

The forward-looking statements included in this Report on Form 6-K are subject to risks, uncertainties and assumptions about the Company’s businesses and business environments. These statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance. Actual results of the Company’s operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People’s Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including the relaxation of China’s one child policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company’s different pricing and payment options and reaction to the introduction of the Company’s premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company’s revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company’s ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a “reverse merger” with an operating company based in the PRC, as well as general economic conditions; the proposed transactions between an affiliate of Golden Meditech Holdings Limited and Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership); and other relevant risks detailed in the Company’s filings with the Securities and Exchange Commission in the United States.

Results of Operations and Financial Condition

Following this cover page are the unaudited condensed consolidated financial results for the three months and six months ended September 30, 2017 of the Company.

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

As of March 31 and September 30, 2017

	March 31,		September 30,
	2017		2017
	RMB		RMB		US$
	(in thousands except share data)

ASSETS
Current assets
Cash and cash equivalents	3,510,264		3,927,280		590,276
Accounts receivable, less allowance for doubtful accounts (March 31, 2017: RMB46,858; September 30, 2017: RMB56,829 (US$8,541))	112,533		111,697		16,789
Inventories	30,987		38,756		5,825
Prepayments and other receivables - Third parties	17,524		22,576		3,394
Prepayments and other receivables - Related parties	—		2,284		343
Total current assets	3,671,308		4,102,593		616,627
Property, plant and equipment, net	551,434		541,612		81,405
Non-current deposits - Third parties	237,487		236,903		35,607
Non-current deposits - Related party	—		8,500		1,278
Non-current accounts receivable, less allowance for doubtful accounts (March 31, 2017: RMB70,744; September 30, 2017: RMB68,696 (US$10,325))	135,148		123,421		18,550
Inventories	68,775		69,843		10,497
Intangible assets, net	106,686		104,376		15,688
Available-for-sale equity securities	200,790		163,038		24,505
Other investment	189,129		189,129		28,426
Deferred tax assets	22,155		25,772		3,874
Total assets	5,182,912		5,565,187		836,457

LIABILITIES
Current liabilities
Convertible notes, net	1,031,154		—		—
Accounts payable	11,060		13,125		1,973
Accrued expenses and other payables	65,162		92,238		13,864
Deferred revenue	323,690		374,912		56,350
Amount due to a related party	4,679		10,428		1,567
Income tax payable	11,383		13,294		1,998
Total current liabilities	1,447,128		503,997		75,752
Non-current deferred revenue	1,569,579		1,728,471		259,792
Other non-current liabilities	302,233		330,455		49,668
Deferred tax liabilities	21,423		20,985		3,154
Total liabilities	3,340,363		2,583,908		388,366

EQUITY
Shareholders’ equity of China Cord Blood Corporation
Ordinary shares
- US$0.0001 par value, 250,000,000 shares authorized, 73,140,147 shares issued and 73,003,248 shares outstanding as of March 31, 2017 and 113,661,641 shares issued and 113,524,742 shares outstanding as of September 30, 2017	50		78		12
Additional paid-in capital	936,417		1,987,057		298,657
Treasury stock, at cost
(March 31 and September 30, 2017: 136,899 shares, respectively)	(2,815	)	(2,815	)	(423	)
Accumulated other comprehensive income/(loss)	24,428		(26,166	)	(3,933	)
Retained earnings	879,775		1,016,505		152,783
Total equity attributable to China Cord Blood Corporation	1,837,855		2,974,659		447,096
Non-controlling interests	4,694		6,620		995
Total equity	1,842,549		2,981,279		448,091
Total liabilities and equity	5,182,912		5,565,187		836,457

CHINA CORD BLOOD CORPORATION

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Three Months and Six Months Ended September 30, 2016 and 2017

	Three months ended September 30,						Six months ended September 30,
	2016		2017				2016		2017
	RMB		RMB		US$		RMB		RMB		US$
	(in thousands except per share data)

Revenues	184,140		234,572		35,257		357,092		458,794		68,958
Direct costs	(39,088	)	(45,644	)	(6,860	)	(76,521	)	(90,426	)	(13,592	)
Gross profit	145,052		188,928		28,397		280,571		368,368		55,366
Operating expenses
Research and development	(2,377	)	(3,664	)	(551	)	(4,326	)	(6,343	)	(953	)
Sales and marketing	(39,642	)	(56,152	)	(8,440	)	(77,834	)	(99,602	)	(14,970	)
General and administrative	(48,289	)	(52,784	)	(7,934	)	(91,532	)	(103,134	)	(15,501	)
Total operating expenses	(90,308	)	(112,600	)	(16,925	)	(173,692	)	(209,079	)	(31,424	)
Operating income	54,744		76,328		11,472		106,879		159,289		23,942
Other (expenses)/income, net
Interest income	4,438		5,790		870		8,715		10,617		1,596
Interest expense	(29,801	)	—		—		(58,634	)	(3,257	)	(490	)
Foreign currency exchange (losses)/gains	(15	)	110		17		120		111		17
Others	576		993		149		728		2,142		322
Total other (expenses)/income, net	(24,802	)	6,893		1,036		(49,071	)	9,613		1,445
Income before income tax	29,942		83,221		12,508		57,808		168,902		25,387
Income tax expense	(12,639	)	(14,525	)	(2,183	)	(24,315	)	(30,246	)	(4,547	)
Net income	17,303		68,696		10,325		33,493		138,656		20,840
Net income attributable to non-controlling interests	(662	)	(1,101	)	(165	)	(1,130	)	(1,926	)	(289	)
Net income attributable to China Cord Blood Corporation’s shareholders	16,641		67,595		10,160		32,363		136,730		20,551

Earnings per share:
Attributable to ordinary shares
- Basic	0.22		0.60		0.09		0.44		1.22		0.18
- Diluted	0.22		0.60		0.09		0.44		1.22		0.18

Other comprehensive losses, net of nil income taxes
- Foreign currency translation adjustments	(1,400	)	(8,376	)	(1,259	)	(8,360	)	(20,107	)	(3,022	)
- Unrealized holding losses in available-for-sale equity securities	(10,507	)	(18,562	)	(2,790	)	(16,977	)	(30,487	)	(4,582	)
Total other comprehensive losses	(11,907	)	(26,938	)	(4,049	)	(25,337	)	(50,594	)	(7,604	)
Comprehensive income	5,396		41,758		6,276		8,156		88,062		13,236

Comprehensive income attributable to non-controlling interests	(662	)	(1,101	)	(165	)	(1,130	)	(1,926	)	(289	)
Comprehensive income attributable to China Cord Blood Corporation’s shareholders	4,734		40,657		6,111		7,026		86,136		12,947

Other Events

On November 20, 201 7, the Company issued a press release announcing unaudited condensed consolidated financial results for the three months and six months ended September 30, 2017. A copy of the press release is attached as Exhibit 99.1.

Exhibits

Exhibit No.		Description

99.1		Press Release dated November 20, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.